Business Context and Reporting Period
This Form 8-K was filed by Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) on May 14, 2021, reporting events occurring on May 11, 2021. The company is a Delaware corporation headquartered in San Diego, California, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the departure of a senior executive:
- Departure: Wendy Johnson notified the company of her intention to retire as Chief Development Officer.
- Effective Date: Her retirement is effective on or before December 31, 2021.
- Reason: She is retiring to pursue personal interests.
Outlook and Management Commentary
Management has announced the immediate commencement of a formal search for a new Chief Development Officer. Ms. Johnson has agreed to assist in identifying a replacement prior to her departure. The filing contains no specific financial guidance, risk factors, or contingencies beyond the standard disclosure of the executive transition.
Investor Verification Checklist
- Confirm the timeline for the appointment of a new Chief Development Officer.
- Review the company's pipeline status to assess the impact of the Chief Development Officer's departure on ongoing clinical trials.
- Verify if any additional executive departures are anticipated in the near term.